Form 4: Skye Bioscience Executive Granted Stock Options

Tuan Tu Diep, Chief Development Officer of Skye Bioscience, receives stock options for 150,000 shares.

Summary

• Tuan Tu Diep, the Chief Development Officer of Skye Bioscience, Inc. [SKYE], was granted stock options on February 24, 2025.
• The options are for 150,000 shares of common stock.
• The exercise price of the options is $2.89 per share.
• The options vest in equal monthly installments over a four-year period, starting February 21, 2025.
• The options expire on February 25, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard part of executive compensation.

Positives

• The granting of stock options to a key executive like the Chief Development Officer can be seen as a positive incentive for them to contribute to the company's long-term success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This grant is a standard part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Comparable companies often use similar vesting schedules (e.g., monthly or quarterly over a 3-4 year period).
• The specific number of shares and exercise price would be benchmarked against companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view this as a positive incentive for the Chief Development Officer.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates